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ABSTRACT
Background: Intraepidermal nerve fiber density (IENFD) is considered a good diagnostic tool for
small fiber neuropathy (SFN).
Objectives: To assess stratified normative values for IENFD and determine the reliability and
validity of IENFD in sarcoidosis.
Methods: IENFD was assessed in 188 healthy volunteers and 72 patients with sarcoidosis (n  58
with SFN symptoms, n  14 without SFN symptoms). Healthy controls were stratified (for age and
sex), resulting in6agegroups (20–29,30–39,…up to70years) containingat least15menand15
women. A skin biopsywas taken in each participant 10cmabove the lateralmalleolus and analyzed in
accordance with the international guidelines using bright-field microscopy. Interobserver/intraob-
server reliability of IENFD was examined. In the patients, a symptoms inventory questionnaire (SIQ;
assessing SFN symptoms) and the Vickrey Peripheral Neuropathy Quality-of-Life Instrument-97
(PNQoL-97) were assessed to examine the discriminative ability of normative IENFD values.
Results: There was a significant age-dependent decrease of IENFD values in healthy controls,
with lower densities in men compared with women. Good interobserver/intraobserver reliability
scores were obtained ( values 0.90). A total of 21 patients with sarcoidosis had a reduced
IENFD score (5th percentile; 19 [32.8%] in patients with SFN symptoms, 2 [14.3%] in patients
without SFN symptoms). The validity of the normative IENFD values was demonstrated by distin-
guishing between the SIQ scores and various PNQoL-97 values for the different patient groups.
Conclusion: This study provides clinically applicable distal intraepidermal nerve fiber density nor-
mative values, showing age- and sex-related differences. Neurology® 2009;73:1142–1148
GLOSSARY
IENFD  intraepidermal nerve fiber density; MUMC  Maastricht University Medical Center; NS  not significant; PNQoL-
97  Vickrey Peripheral Neuropathy Quality-of-Life Instrument-97; SFN  small fiber neuropathy; SIQ  symptoms inven-
tory questionnaire.
Investigating sensory symptoms can be a diagnostic challenge. When a neuropathy is consid-
ered, neurologic examination and nerve conduction studies generally do not reveal abnormali-
ties if predominantly small fibers are affected.1 There is no gold standard for diagnosing small
fiber neuropathy (SFN), though a sensory neuropathy may present with small fiber involve-
ment or indicate a disease causing pure small fiber dysfunction.2 Typically, patients with SFN
report burning pain in the extremities, combined with autonomic dysfunction, such as dry
eyes, changes in sweating, and gastrointestinal and urogenital dysfunction.3
Quantitative sensory testing such as temperature detection thresholds, sudomotor axon
reflex, and cardiovascular autonomic testing are available techniques to determine small nerve
fiber function. However, some tests have disadvantages, such as subjectivity, high burden for
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patients, or low sensitivity and specificity.4 In
SFN, loss of intraepidermal nerves is consid-
ered an objective diagnostic feature.5
There are several potentially treatable ill-
nesses that may cause SFN. Diabetes mellitus
is the most frequent underlying disease, but
several other metabolic, inflammatory, and
hereditary disorders cause SFN.2 Recently,
SFN was demonstrated to occur in sarcoid-
osis.6 Only a small sample of patients with
sarcoidosis has been examined so far.
Determination of intraepidermal nerve fi-
ber density (IENFD) is considered a reliable
technique to assess loss and regeneration of
small nerve fibers. Several techniques have
been adopted; the most commonly used are
bright field immunohistochemistry and indirect
immunofluorescence on punch biopsies.7-9
Reported interobserver/intraobserver variability
is good.10
The aims of the current study are to present
normative IENFD values, stratified for age and
sex, for a collaborative group (Maastricht, The
Netherlands; Milan and Ferrara, Italy), and to
examine the interobserver/intraobserver reliabil-
ity and discriminatory validity of IENFD in a
cohort of patients with sarcoidosis.
METHODS Participants. Healthy controls. Healthy con-
trols were recruited from hospital personnel, from relatives and
friends of patients, at sports accommodations, and at informal
meetings for the elderly, in The Netherlands and Italy. Healthy
individuals were stratified for age and sex, forming 6 age groups
(20–29, 30–39, 40–49, . . . up to 70 years and older) consisting
of at least 15 men and 15 women each. Eligibility criteria were
lucid consciousness, no neurologic symptoms, no history of alco-
hol misuse (defined as4 IU/day), no use of drugs or history of
diseases that may cause sensory deficit (e.g., chemotherapeutic
agents in the past, malignancy, diabetes mellitus, thyroid dys-
function, renal failure, peripheral vascular disease, skin disor-
ders), and normal findings at neurologic examination.
Patients. From October 2006 to June 2008, patients re-
ferred to the Maastricht Sarcoidosis Management Center, a re-
ferral center for sarcoidosis in The Netherlands, were screened
for eligibility. Inclusion criteria for the study were age older than
18 years, no alcohol abuse, no use of immunosuppressant or
neuropathy-causing drugs, no concomitant disease possibly caus-
ing SFN (normal laboratory findings for glucose, thyroid func-
tion, blood count, and renal and liver function tests), and a
neurologic examination without signs of large fiber neuropathy
or CNS involvement. Furthermore, nerve conduction findings
(assessing median, peroneal, and tibial motor nerves, and median
and sural sensory nerves under predefined conditions) had to be
normal. All patients were diagnosed as having sarcoidosis in accor-
dance with postulated diagnostic guidelines.11 We only recruited
therapy-naive patients or patients who had not received immuno-
suppressive therapy in the 6 months before inclusion, because the
effect of these medications on small nerve fibers is unknown.
Assessments. Skin biopsy. Published European guidelines on
the use of skin biopsy in the diagnosis of SFN were used.7 A
3-mm punch biopsy was performed under local anesthesia (1%
lidocaine) 10 cm above the right lateral malleolus in all subjects.
All biopsies were fixed in 2% paraformaldehyde-lysine-
sodiummetaperiodate and stored at 80°C in a cryoprotective
solution (20% glycerol) before further processing. After cutting
(Microm, HM560 Cryostar, Walldorf, Germany), the 50-m-
thick sections were immunostained using a free-floating method:
after bleaching, the sections were blocked with goat serum, incu-
bated with the panaxonal marker PGP 9.5 (Ultraclone, Wellow,
Isle of Wight, UK), and secondary antibody (biotinylated anti-
rabbit immunoglobulin G, Biozol, Eching, Germany). The reac-
tion was then visualized after endogenous peroxidase blocking,
with the Vectastain ABC kit and Vector SG substrate kit (Vector
Laboratories, Burlingame, CA). Epidermal length was measured
and sections were counted with bright field microscopy on a stereol-
ogy workstation (Olympus BX50 with PlanApo objective 40 [oil;
NA  1.0], Tokyo, Japan, and stereology software Stereo-
Investigator version 7.00.3, Micro-BrightField, Williston, VT), ap-
plying the established counting rules.12 In brief, the rules state that to
be counted, intraepidermal nerves have to cross or originate at the
dermal-epidermal junction, and secondary branches and fragments
are not counted. After fixing the specimens, at least 3 sections were
analyzed under the light microscope. IENFD is reported as the
mean IENF of these 3 sections per millimeter.
SFN symptoms inventory questionnaire. A simple SFN
symptoms inventory questionnaire (SIQ) was constructed, based on
international guidelines.13,14 The SIQ includes 12 inquiries address-
ing the following aspects: presence of palpitations, flushes, constipa-
tion or diarrhea, urination problems (incontinence or hesitation),
changes in sweating pattern, restless legs, orthostatic dizziness, dry
eyes or mouth, oversensitivity and sheet intolerance of the legs.
Items focused on the presence or absence of these symptoms (0 
no symptoms to 12maximum number of symptoms).
Vickrey Peripheral Neuropathy Quality-of-Life
Instrument-97. The Vickrey Peripheral Neuropathy Quality-
of-Life Instrument-97 (PNQoL-97) has the Short-Form 36-
Item Health Survey as a generic core, supplemented with
specifically neuropathy related questions, resulting in a 97-item
scale, with 91 items distributed among 16 multiscale domains
and 6 separately scored questions.15,16 The domains are physical
functioning (11 items), role limitations due to physical health prob-
lems (6 items), pain (7), energy/fatigue (5), upper extremities (6),
balance (8), self-esteem (6), emotional well-being (7), stigma (3),
cognitive function (3), role limitations due to emotional problems
(3), general health perceptions (7), sleep (5), social functioning (9),
sexual function (2), and health distress (3).16 Each domain has a
scoring range from 0 to 100. A high score indicates better health. For
the purpose of the current study, the original PNQoL-97 was
translated–back-translated by 2 independent translators into Dutch in
accordance with international guidelines.14 Ambiguous items were dis-
cussed until uniformity was obtained on all items. The Vickrey
PNQoL-97 physical and mental component summary score (V-PCS,
V-MCS) values were calculated.16-18
Standard protocol approvals, registration, and patient
consent. The study was approved by the medical ethical com-
mittees of all participating centers and the CCMO (Central
Committee for Human Related Research, identifier number
p06.0066L/MEC 05-224). Written informed consent was ob-
tained from all participants before inclusion.
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Study design. General aspects. Examination occurred in a
comfortable, temperature-controlled room. All participants un-
derwent a standardized interview, neurologic examination, and
skin biopsy by a skilled investigator (M.B.). All selected patients
were recruited at the department of neurology of the Maastricht
University Medical Center (MUMC), The Netherlands. A pa-
tient was classified as having SFN symptoms when he or she
reported at least 1 of the following symptoms, not otherwise
explained: burning pain in extremities, dry mouth or eyes,
changes in sweating, flushes, gastrointestinal dysfunction (con-
stipation, diarrhea), cardiac symptoms (palpitation, dizziness on
standing up), and urogenital dysfunction (sexual dysfunction,
incontinence). Those without any of these symptoms were clas-
sified as having no SFN symptoms (patient control group). All
patients completed the SIQ and PNQoL-97.
Reliability studies. All biopsies were coded, thus blinding
the examiners. The IENFD of all participants at the MUMCwas
counted by 1 researcher (M.B.). Fifty randomly selected slides
(25 patients plus 25 healthy controls) were also analyzed by a
second examiner (C.G.F.) (local IENFD interobserver reliabil-
ity). These 50 slides were recounted by the examiners (interval at
least 2 weeks) for the IENFD intraobserver reliability scores of
both examiners, without having access to the earlier findings. To
determine interobserver reliability between laboratories, examin-
ers at Milan (R.L.), Ferrara (G.D.), and Maastricht (M.B.) each
counted 30 arbitrarily selected slides (healthy controls; 10 slides
per center, circulating between institutes).
The SIQ was completed twice (interval: 2–4 weeks) to ex-
amine its test-retest reliability.
Validity studies. The validity of the IENFD normative val-
ues was examined through discriminatory studies with the SIQ
and PNQoL-97 domains and component sum scores in the pa-
tient group. In particular, we examined whether the normative
data would help to discriminate between the obtained scores in
these outcome measures that are based on patients’ own percep-
tion (sarcoidosis patients without SFN symptoms vs those pa-
tients with SFN symptoms but normal IENFD scores vs those
with SFN symptoms and abnormal IENFD).
Statistical analysis. Data handling and normative values.
Data collection, entry, and management were performed using
the Teleform automated processing system, striving to reduce
the number of manual data entry errors.19 All analyses were per-
formed using Stata 10.0 for Windows XP (StataCorp LP, Col-
lege Station, TX). A value of p  0.05 was considered
significant.
Normative IENFD reference values were calculated in
healthy controls (5th percentile values, corresponding to a cho-
sen specificity of 95%), depending primarily on age and sex.
Quantile regression analyses were performed to obtain the nor-
mative data. A patient’s IENFD was considered to be abnormal
if the corresponding value was below the normative data 5th
percentile lower limit, because this cutoff value has previously
been used.20 Weight and height were analyzed for possible corre-
lating confounding impact on IENFD normative values.
Reliability studies. Interobserver and intraobserver reliabil-
ity scores for the IENFD and SIQ test-retest reliability were de-
termined using weighted  statistic measures.21 The weights of
the  were defined as 1  [(i  j)/(k  1)]2 (i  rows and j 
columns of the ratings by 2 observers or by the patients twice in
time, k  maximum number of possible ratings).
Validity studies. The discriminative capacity of the ob-
tained IENFD normative values was investigated in 3 subgroups
of patients (subgroup A: sarcoidosis patients without SFN symp-
toms; subgroup B: sarcoidosis patients with SFN symptoms but
normal IENFD values; subgroup C: sarcoidosis patients with
SFN symptoms and impaired IENFD scores [5th percentile
lower limit]) by comparing the obtained scores for SIQ plus
PNQoL-97 values in the patient subgroups (analysis of variance
with corrections according to Bonferroni multiple comparison
tests for continuous variables; 2 test for ordinal variables).
RESULTS General aspects. Recruitment was per-
formed between January 2006 and June 2008. Skin
biopsies were collected in 188 healthy volunteers
(Maastricht n  105, Milan n  44, Ferrara n 
39), stratifying for age decade and sex (15 men and
15 women per age decade, range 20–82 years and
older, forming 6 age decades). Most volunteers were
white (97%).
Between October 2006 and June 2008, 211 pa-
tients with sarcoidosis were referred to the MUMC
(figure e-1 on the Neurology® Web site at www.
neurology.org). Reasons for exclusion were immuno-
suppressive treatment (65), comorbidity that could
cause neuropathy (30), CNS involvement (11) and
large nerve fiber involvement found at neurologic or
nerve conduction studies (21), and inability or un-
willingness to attend examination (9). Eventually, 72
patients met the inclusion criteria and declared will-
ingness to participate. Of these 72 patients, 58 were
categorized as having symptoms not otherwise ex-
plained and possibly caused by SFN, and 14 were
categorized as not having any SFN-related symp-
toms. All patients mentioned fatigue as one of their
main problems. The participants’ characteristics are
presented in table 1. No complications were encoun-
tered in either healthy volunteers or patients due to
the skin biopsy.
Normative values. Normative IENFD reference val-
ues were calculated in 188 healthy controls. There
was a significant age-dependent decrease of IENFD
values, with lower scores for men compared with
women (figure 1). Height and weight did not have
any significant impact on the IENFD scores. The
obtained normative scores were subsequently trans-
lated per age span and sex for clinical use, using the
5th percentile as a cutoff value (table 2).
Reliability and discriminative validity studies. Good
intraobserver reliability values were obtained for both
researchers in Maastricht (MB.: weighted   0.95;
C.G.F.: 0.90), with good interobserver scores as well
(0.94). There was also a good interobserver reliability
between the examiners at the 3 institutes: Maas-
tricht-Milan: weighted   0.78; Maastricht-Fer-
rara: 0.83; Milan-Ferrara: 0.91.
In the subgroup of patients with sarcoidosis and
possible SFN symptoms (n  58), 19 patients
(32.8%) had impaired IENFD scores. In contrast, all
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patients without SFN symptoms except 2 (14.3%)
had normal IENFD values (2 test: p  0.17). For
further discriminative validity studies, we divided the
patients with SFN symptoms into those with
IENFD being normal and those with IENFD 5th
percentile lower limit, ultimately having 3 subgroups
for comparison (subgroup A: sarcoidosis without
SFN symptoms, n  14; subgroup B: sarcoidosis
with SFN symptoms, normal IENFD findings, n 
39; subgroup C: sarcoidosis with SFN symptoms and
abnormal IENFD values, n  19). Figure 2 illus-
trates that more SFN-related symptoms as reported
by SIQ are present in patients with abnormal
IENFD, with a gradual transition between the 3 sub-
groups (2 test between subgroups: p  0.001). Hy-
persensitivity is reported by 14% in subgroup A, by
69% in subgroup B, and by 79% in subgroup C.
Similar differences for symptoms of dry mouth
(50%, 72%, 79%) and orthostatic intolerance (36%,
67%, 84%) were found. Presence of SFN symptoms
in subgroup A was comparable to that in healthy
controls (data not shown). The SIQ demonstrated
good test-retest reliability (weighted   0.88).
A significant discriminative validity was obtained
when comparing the results of the PNQoL-97 do-
mains between the 3 subgroups for pain, balance,
energy/fatigue, upper extremity function, cognitive
functioning, and social functioning. Also, the physi-
cal component score of this scale (V-PCS) showed a
discriminative trend between the 3 subgroups of pa-
tients (table 3). In general, these PNQoL-97 do-
mains and V-PCS did not significantly differentiate
between subgroups B and C, patients with SFN
symptoms, but showed a trend of more reduced
quality-of-life features in those with abnormal
IENFD (table 3). The remaining domains and
Figure 1 IENFD of 188 healthy individuals
Scatterplot showing normative intraepidermal nerve fiber density (IENFD) scores in healthy individuals stratified for age and sex (5th and 50th percentiles
shown).
Table 1 Basic characteristics of healthy controls and patients with
sarcoidosis, with or without small fiber neuropathy symptoms
Healthy
controls
Sarcoidosis
patients with
SFN symptoms
Sarcoidosis
patients without
SFN symptoms
n 188 58 14
Sex, n (%)
Female 97 (51.6) 25 (43.1) 7 (50)
Male 91 (48.4) 33 (56.9) 7 (50)
Age, mean (SD), range, y 47.0 (15.8), 20–82 45.4 (9.2), 29–70 46.5 (9.5), 27–65
Duration of symptoms,
mean (SD), range, y
— 7.9 (6.0), 1–32 9.4 (7.3), 2–28
Main initial reported
symptom*,%
Burning feet — 1.7 —
Pain† — 27.6 28.6
Pulmonary‡ — 32.8 28.6
Fatigue — 6.9 7.1
Main current reported
symptoms*,%
Burning feet — 29.3 —
Pain† — 53.4 28.5
Pulmonary‡ — 6.9 42.9
Fatigue — 96.6 85.7
*Does not add up to 100%because of not separately mentioned symptoms (skin abnormal-
ities, different autonomic symptoms, uveitis, fever, and weight loss).
†Various pain modalities were addressed: thoracic pain, joint pain, other pain in extremities,
such as muscle pain.
‡Dyspnea and cough were mentioned as the main pulmonary symptoms.
SFN small fiber neuropathy.
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V-MCS did not show any difference between the
subgroups of patients.
DISCUSSION In the current study, we described
the determination of the largest series of normative
distal leg IENFD values, stratified for age and sex.
We demonstrated good interobserver/intraobserver
reliability and acceptable IENFD validity scores
through association with questionnaires. This series
of skin biopsies is available for other researchers in-
terested in joining a quality control program and in
enlarging their normative reference values. Norma-
tive data for IENFD have been reported previously
for the same location.20,22-24 Our results differ (lower
values) from previous reports on IENFD normative
values, which is most probably explained by differ-
ences in sample size of healthy controls and in count-
ing rules. We found lower IENFD values in men
compared with women, and an age-related decrease
in IENFD, which is in conformity with these earlier
reports.
Several neurologic tests have shown decreased
function in healthy elderly, such as diminished grip
strength, temperature and vibration sensation, and
nerve conduction studies.25-28 Also, women have
been reported to be more sensitive in quantitative
sensory testing.29,30 On the structural level, age-
related decline is noted too, for example, in Meissner
and Pacinian corpuscles.31,32 The reasons for age-
related decline and sex differences may be related to
differences in hormonal status.33 Progesterone and its
metabolites, for example, stimulate axonal growth
and myelinization. Though it is also synthesized in
the nervous system, in female rats, it is more abun-
dant because of the gonadal production, and in ex-
perimental studies, nerve sprouting, regeneration,
and remyelinization are more rapid and more com-
plete in female animals.34,35
In our series, we were able to identify one-third of
sarcoidosis patients with SFN using only sex- and
age-related cutoff IENFD normative values. Our
IENFD sensitivity turned out to be lower compared
with reported literature findings, which is most prob-
ably related to differences in population of patients
examined and differences in IENFD cutoff
values.36-38 We only included patients with pure
small fiber–related symptoms and excluded patients
with large fiber neuropathy. Others have examined
Table 2 Intraepidermal nerve fiber density normative values for clinical use
Women (n 97) Men (n 91)
Age, y
0.05 quantile
IENFD values per
age span
Median IENFD
values per
age span
0.05 quantile
IENFD values per
age span
Median IENFD
values per
age span
20–29 6.7 11.2 5.4 9.0
30–39 6.1 10.7 4.7 8.4
40–49 5.2 9.9 4.0 7.8
50–59 4.1 8.7 3.2 7.1
60–69 3.3 7.9 2.4 6.3
>70 2.7 7.2 2.0 5.9
IENFD intraepidermal nerve fiber density.
Figure 2 Discriminative validity of IENFD values related to the symptoms inventory questionnaire score
in sarcoidosis
Bar chart showing patients with few (0–3), some (4–7), a lot (8–11), and all 12 symptoms, divided per subgroup: subgroup
A, black (n  14): patients classified as having no small fiber neuropathy (SFN) symptoms; subgroup B, white (n  39):
patients classified as having SFN symptoms, but normal intraepidermal nerve fiber density (IENFD) at examination; sub-
group C, gray (n 19): patients classified as having SFN symptoms and abnormal IENFD.
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patients with sensory neuropathy symptoms (thus
having thick nerve fiber involvement) and have dem-
onstrated higher sensitivity of reduced IENFD in
these patients compared with those with only small
nerve fiber involvement.37,38 Progression from pure
SFN to large fiber involvement in patients over time
with further reduction of IENFD in these patients has
also been reported, hence underlining the notion of a
continuum and progressive disease pattern.36
The current article addresses discriminatory valid-
ity between subgroups of patients with sarcoidosis,
translating pathology (small fiber findings in skin bi-
opsy) to impairments (SFN symptoms) and partly to
quality-of-life expectations, by demonstrating differ-
ences between sarcoidosis patients without SFN
symptoms vs those with SFN symptoms but normal
IENFD vs those with SFN symptoms and impaired
IENFD. Similar findings have been reported in pa-
tients with various forms of inflammatory neuropa-
thies.39 Although not significant, patients with SFN
symptoms and impaired IENFD had more physically
oriented symptoms, such as more pain, less energy,
and more balance problems, and more social dys-
function compared with the other subgroups. Emo-
tional items scores did not differ between subgroups,
thus excluding emotional problems as an explanation
for patients’ dysfunction. Hence, low IENFD con-
tributes to the patients’ daily symptoms and physical
burden and helps clinicians in understanding its im-
pact in patients with sarcoidosis.
There are some methodologic issues that should
be addressed. First, a gold standard for the diagnosis
SFN was proposed: the presence of at least 2 abnormal
results at clinical, QST, and skin biopsy examinations.36
However, the validation of this proposition is beyond
the scope of the current study. Second, some caution is
required when interpreting the results, because the sam-
ple sizes of the various subgroups were relatively small.
Third, efforts were taken to subdivide the 72 selected
patients into 3 subgroups based on a systematic inter-
view focusing on the presence of SFN symptoms. De-
spite these efforts, patients of the subgroup without any
SFN symptoms (subgroup A) reported through the
SIQ questionnaire some presence of symptoms, al-
though relatively low compared with the other 2 sub-
groups of patients (figure 2). However, the presence of
symptoms in subgroup A was similar to that in healthy
controls. Finally, we have not systematically examined
whether skin type or occupation might have any influ-
ence on IENFD.
The current study presents clinically applicable
distal leg IENFD values, supporting previously re-
ported age- and sex-related differences. Validity
through association with an SFN-specific and ge-
neric quality-of-life questionnaire was acceptable.
Hence, IENFD is suggested as an alternative end-
point in future clinical trials in neuropathies, as has
been addressed previously.40 Further study in pa-
tients with SFN and validation of a possible gold
standard are recommended.
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Table 3 Comparison of PNQoL-97 domain scores between subgroups of
patients with sarcoidosis
Domain
Subgroup
comparison* A vs B† A vs C† B vs C†
Pain 0.0001 0.0001 0.0001 0.057
Balance 0.0001 0.003 0.0001 NS
Energy/fatigue 0.01 NS 0.02 NS
Upper extremities
function
0.004 0.01 0.005 NS
Cognitive functioning 0.04 0.01 NS NS
Social functioning 0.04 0.03 NS NS
Physical component
score
0.0004 0.002 0.0001 NS
Data are p values.
*Overall result from analysis of variance with corrections according to Bonferroni multiple
comparison tests.
†Subgroup A: patients without small fiber neuropathy (SFN)–related symptoms; subgroup B:
patients with SFN-related symptoms and normal intraepidermal nerve fiber density
(IENFD); subgroup C: patients with SFN-related symptoms and reduced IENFD.
PNQoL-97  Vickrey Peripheral Neuropathy Quality-of-Life Instrument-97; NS  not
significant.
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